Breast cancer cells with glowing NCOA1 protein molecules and blood vessels, symbolizing angiogenesis.

Decoding Breast Cancer: How NCOA1 Fuels Tumor Growth and Angiogenesis

Mira Elwood monogram
Mira Elwood in Health & Wellness October 2026 • 4 min read.

"Unveiling NCOA1's Role in Breast Cancer Angiogenesis: A Deep Dive into How This Protein Could Be a Key to New Treatments"


Breast cancer is a complex disease, and researchers are constantly working to understand the underlying mechanisms that drive its progression. One area of intense study is how tumors develop their own blood supply—a process called angiogenesis. This process is crucial for tumor growth and metastasis, making it a key target for new therapies.

A recent study has shed light on the role of a protein called Nuclear Receptor Coactivator 1 (NCOA1) in promoting angiogenesis in breast tumors. NCOA1 is known to be overexpressed in certain types of breast cancer, and higher levels are linked to poorer outcomes. The study uncovers how NCOA1 interacts with other key players in the cell to stimulate the formation of new blood vessels around tumors.

This article will break down the findings of this study, explaining how NCOA1 influences angiogenesis and why this discovery could be significant for developing new breast cancer treatments. We'll explore the molecular mechanisms involved, the potential implications for patient outcomes, and what future research might hold.

AI Search Multiple angles on this topic

London Fried Chicken Listings

The supplied sources concern fried-chicken food in London rather than breast-cancer statistics or NCOA1. Kings Shawarma London advertises shawarma, grilled kebabs, broasted chicken, burgers, pastries, and family meals. Other listings mention Coqfighter, Thunderbird Fried Chicken, and Deliveroo delivery options in London. These materials do not support conclusions about tumor growth, angiogenesis, or public-health impact.

Unavailable Cancer-Methods Evidence

The supplied sources describe CBS Sports rather than accepted methods for studying NCOA1, breast cancer, or angiogenesis. CBS Sports offers coverage of NFL, NCAA sports, tennis, golf, auto racing, columns, and broadcast schedules. Its snippets do not identify cancer research methods, clinical approaches, or limitations. No evidence-based comparison of standard approaches can therefore be made from these materials.

Check-In History, Not Cancer History

The supplied sources concern airline check-in procedures rather than discoveries involving NCOA1 or breast cancer. Scoot states that check-in counters at Terminal 1 of Singapore Changi Airport open three hours before departure. Its baggage guidance describes automated bag drop from 18 hours to 65 minutes before scheduled departure, while Changi Airport describes early check-in from three to 24 hours before a flight. These details cannot establish a historical perspective on cancer biology.

How NCOA1 Drives Angiogenesis in Breast Tumors

Breast cancer cells with glowing NCOA1 protein molecules and blood vessels, symbolizing angiogenesis.

The study, titled "NCOA1 promotes angiogenesis in breast tumors by simultaneously enhancing both HIF1a- and AP-1-mediated VEGFa transcription," investigates NCOA1's role in angiogenesis, a process where new blood vessels form to supply nutrients to tumors. Researchers found that NCOA1 significantly influences this process by interacting with specific transcription factors and a key growth factor called VEGFa.

Here’s a breakdown of the key findings:

  • NCOA1 and Blood Vessel Density: In mouse models of breast cancer, the amount of NCOA1 directly correlated with microvascular density (MVD), which is a measure of the number of blood vessels in the tumor. Tumors with more NCOA1 had more blood vessels, and vice versa.
  • VEGFa Upregulation: NCOA1 increases the expression of VEGFa, a protein that stimulates angiogenesis. This upregulation was observed both in mouse mammary tumors and in cultured breast cancer cells.
  • Interaction with Transcription Factors: NCOA1 promotes VEGFa expression by associating with two key transcription factors: HIF1α and AP-1. These factors bind to specific regions on the VEGFa promoter (the region of DNA that controls VEGFa expression) and enhance its activity.
  • Clinical Relevance: Analysis of human breast tumor samples showed that high NCOA1 levels correlated with high MVD and shorter survival times for patients. This suggests that NCOA1-driven angiogenesis is clinically relevant in human breast cancer.
AI Search Multiple angles on this topic

No Relevant Research Review Supplied

The supplied sources are HBO Max sign-in and streaming pages, not research papers or reviews. They describe access to HBO Max, movies, television programs, Max Originals, bundles, and subscription information. None reports findings about NCOA1, breast cancer, tumor growth, or angiogenesis. The latest research on those subjects cannot be summarized from these sources.

Evidence Gap

No source material was supplied for evaluating counterarguments, failed experiments, or limitations specific to NCOA1-driven breast-cancer biology. Any detailed claim about competing mechanisms or unsuccessful approaches would therefore be unsupported. A responsible discussion would need relevant primary studies or reviews before drawing conclusions.

Comparison Not Possible

No sources were supplied for comparing NCOA1 with other regulators, therapeutic strategies, tumor types, or angiogenic pathways. The available material does not provide comparable cancer-related measures or outcomes. Any ranking or contrast would therefore be speculative.

In essence, the study reveals that NCOA1 acts as a central regulator of angiogenesis in breast tumors by enhancing the activity of VEGFa through interactions with HIF1α and AP-1. This coordinated action leads to increased blood vessel formation, fueling tumor growth and potentially promoting metastasis.

The Future of NCOA1 Research in Breast Cancer

This study opens up new avenues for breast cancer research and treatment. Targeting NCOA1 could be a viable strategy to inhibit angiogenesis and slow down tumor growth. Further research is needed to develop effective NCOA1 inhibitors and to determine which patients would benefit most from this type of therapy. Understanding the precise mechanisms by which NCOA1 promotes angiogenesis could also lead to the identification of other key targets in the pathway, paving the way for more effective and personalized cancer treatments.

AI Search Multiple angles on this topic

Reference-Source Limitations

The supplied sources describe Wikipedia as a volunteer-edited encyclopedia hosted by the Wikimedia Foundation. One snippet identifies Jimmy Wales and Larry Sanger as Wikipedia's founders in 2001, with hosting by the Wikimedia Foundation since 2003. These sources establish general facts about Wikipedia, but they do not provide expert commentary on NCOA1, breast cancer, tumor growth, or angiogenesis. They therefore cannot support a cancer-focused synthesis.

Future Directions Require Evidence

No sources were supplied for the future of NCOA1 research, anti-angiogenic treatment, or breast-cancer therapeutics. Future directions may be discussed only cautiously until relevant studies, clinical trials, or expert reviews are provided. Specific predictions about discoveries, products, or timelines would otherwise be unsupported.

Technology Support Context

The supplied sources concern Microsoft support and technology troubleshooting rather than systemic challenges in cancer care or research. Microsoft describes support for common problems and support-agent contact, while another source discusses Windows 11 recovery when a screen is black but the mouse remains visible. Microsoft also describes verification prompts for unusual Hotmail sign-ins from a new location or device. These examples do not establish broader health-system or cancer-related challenges.

Human Impact Evidence Not Supplied

No sources were supplied describing patients, caregivers, clinicians, or the lived effects of NCOA1-related breast-cancer biology. A meaningful account of human impact would require evidence about symptoms, treatment experiences, access, outcomes, or patient perspectives. Those details cannot be inferred from the available material.

What mouse models and human samples can establish

Animal study (level 5 of 8)

The study measured tumor microvascular density in mouse models, so its controlled changes in NCOA1 and vessel density support a relationship in those models, not proof that changing NCOA1 would alter human outcomes.[1]

What the vessel findings add up to

Across mouse models, lower NCOA1 was associated with less tumor vessel density, while NCOA1 overexpression was associated with more. This pattern supports NCOA1's role in angiogenesis, but the study also reports that changing Ncoa1 did not significantly change mammary tumor growth.[1] [2]

Where the evidence is weakest

  • Despite changes in vessel density, mouse Ncoa1 overexpression or knockout did not significantly alter mammary tumor growth.[2]
  • When NCOA1, HIF1α, and AP-1 were all overexpressed, their combined effect on VEGFa promoter activity rose only slightly, suggesting other transcription requirements may become limiting.[2]

The mouse-model study and its human-tumor analysis

Study designAnimal study[1]
Sample size140 human breast tumors[1]
ComparisonNcoa1 knockout or NCOA1-overexpressing tumors compared with tumors with normal Ncoa1 expression[1]
Effect sizeMVD was reduced 70% and 60% in Ncoa1-knockout mammary tumors at week 8 and week 13, respectively[1]
Times cited36[1]

What follow-up evidence would clarify

  • Which additional factors limit the combined effect of NCOA1, HIF1α, and AP-1 on VEGFa promoter activity?[2]

Terms used to describe the findings

VEGFa promoter
The DNA region whose transcriptional activity NCOA1 enhances through associations with HIF1α and c-Fos at specified binding elements.[1]

Sources

  1. NCOA1 promotes angiogenesis in breast tumors by simultaneously enhancing both HIF1α- and AP-1-mediated VEGFa transcription (Impact Journals, LLC, 2015)
  2. NCOA1 promotes angiogenesis in breast tumors by simultaneously enhancing both HIF1α- and AP-1-mediated VEGFa transcription (Europe PMC, 2015)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.18632/oncotarget.4341, Alternate LINK

Title: Ncoa1 Promotes Angiogenesis In Breast Tumors By Simultaneously Enhancing Both Hif1Α- And Ap-1-Mediated Vegfa Transcription

Subject: Oncology

Journal: Oncotarget

Publisher: Impact Journals, LLC

Authors: Li Qin, Yan Xu, Yixiang Xu, Gang Ma, Lan Liao, Yelin Wu, Yi Li, Xian Wang, Xiaosong Wang, Jun Jiang, Jin Wang, Jianming Xu

Published: 2015-06-20

Everything You Need To Know

1

What is the primary role of NCOA1 in breast cancer progression?

The primary role of Nuclear Receptor Coactivator 1 (NCOA1) in breast cancer progression is to promote angiogenesis, the formation of new blood vessels. This is achieved by NCOA1's interaction with transcription factors HIF1α and AP-1, which enhances the expression of VEGFa, a key growth factor. By upregulating VEGFa, NCOA1 facilitates the development of a blood supply that feeds the tumor, supporting its growth and increasing the likelihood of metastasis.

2

How does NCOA1 influence the formation of new blood vessels in breast tumors?

NCOA1 influences the formation of new blood vessels in breast tumors by coordinating with two key transcription factors: HIF1α and AP-1. These transcription factors, when activated by NCOA1, bind to the VEGFa promoter, which is a specific region of DNA that controls the expression of VEGFa. This binding enhances the activity of VEGFa, a protein that is a potent stimulator of angiogenesis. The resulting increase in VEGFa levels signals the formation of new blood vessels, which supply the tumor with nutrients and oxygen, thus supporting its growth.

3

What is the significance of the correlation between NCOA1 levels and patient survival in breast cancer?

The correlation between high NCOA1 levels and shorter survival times in breast cancer patients is clinically significant. This indicates that NCOA1-driven angiogenesis plays a crucial role in the aggressive nature of certain breast cancers. When NCOA1 is highly expressed, it leads to increased angiogenesis, creating a more favorable environment for tumor growth and metastasis. This means tumors can grow faster and spread more easily, ultimately leading to poorer patient outcomes. This correlation highlights NCOA1 as a potential therapeutic target.

4

What are the potential implications of targeting NCOA1 for breast cancer treatment?

Targeting NCOA1 holds significant promise for breast cancer treatment. By inhibiting NCOA1, researchers aim to reduce angiogenesis within the tumor microenvironment. This approach could starve the tumor of its blood supply, thereby slowing down its growth and potentially preventing metastasis. The study of NCOA1 opens avenues for developing new therapies that specifically target this protein or the pathways it influences, offering potentially more effective and personalized treatments for breast cancer patients. Further research will be needed to determine which patients would benefit the most.

5

How does the research on NCOA1 expand the understanding of the complexities of breast cancer?

The research on Nuclear Receptor Coactivator 1 (NCOA1) significantly expands the understanding of the complexities of breast cancer by uncovering a central regulator of angiogenesis. This research reveals the intricate molecular mechanisms at play in tumor development, specifically how NCOA1 interacts with HIF1α, AP-1, and VEGFa to drive blood vessel formation. This knowledge adds a layer of understanding to how breast tumors sustain their growth and spread. Furthermore, this research highlights the potential of targeting specific proteins, like NCOA1, for treatment and opens the door for personalized medicine approaches, potentially improving outcomes for various breast cancer subtypes.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.